COMMUNIQUÉS West-GlobeNewswire

BrightSpring Health Services Applauds Hundreds of Award-Winning Employees for their Recognition of Outstanding Service and Care

04/04/2024 - 13:30

LOUISVILLE, Ky., April 04, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or “the Company”) (NASDAQ: BTSG) applauds its most recent employees and programs for their dedicated service, care, [...]

HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations

04/04/2024 - 13:30

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce further expansion of HealthTab™ with Rexall [...]

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

04/04/2024 - 13:15

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human [...]

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

04/04/2024 - 13:05

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief [...]

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

04/04/2024 - 13:05

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

04/04/2024 - 13:00

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs [...]

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

04/04/2024 - 13:00

Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “ [...]

Tilray Brands Announces 420 Activations Across Canada and Unveils Celebratory Product Lineup

04/04/2024 - 13:00

Tilray Releases New Product Innovations Across Core Recreational Cannabis Categories from Whole Flower, Beverages, Pre-rolls, and Vapes TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (Nasdaq [...]

Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

04/04/2024 - 13:00

The partnership enables Augmedix to accelerate scaling efforts for digital health solutions and integrations that work seamlessly at the point of care SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: [...]

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

04/04/2024 - 13:00

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting [...]

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting

04/04/2024 - 13:00

Company to share new data on the use of AI-powered protein design to program T cell therapies for unprecedented efficacy in the treatment of solid tumors Seattle, WA, April 04, 2024 (GLOBE NEWSWIRE) -- Outpace Bio , a [...]

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

04/04/2024 - 13:00

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in [...]

Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

04/04/2024 - 13:00

TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

04/04/2024 - 12:50

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema [...]

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

04/04/2024 - 12:50

--ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : [...]

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

04/04/2024 - 12:45

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the [...]

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

04/04/2024 - 12:30

– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in [...]

Oculis to Participate at Upcoming April Investor Conferences

04/04/2024 - 12:30

ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that [...]

Notice convening the Annual General Meeting in BioPorto A/S

04/04/2024 - 11:07

April 4, 2024 Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on [...]